Transform-HTN
50 evidence topics · 14 sources
Objective
Purpose stated in the ClinicalTrials.gov record
Purpose stated by the sponsor
Role of the trial in the new drug application
Scope of the AHA Scientific Sessions 2026 presentation
Location and study date
Study dates and status in the ClinicalTrials.gov record
“Study Start (Actual) 2023-07-14” (opens the source at this quote in a new tab)
“Primary Completion (Actual) 2025-12-30” (opens the source at this quote in a new tab)
“Study Completion (Estimated) 2027-05” (opens the source at this quote in a new tab)
“Active, not recruiting” (opens the source at this quote in a new tab)
Registered locations
Other study identifiers
Presentation of results
Study design
Design details in the ClinicalTrials.gov record
| Field | Quoted record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “Non-Randomized” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Phase | “Phase 3” |
| Enrollment | “1076” |
Open-label treatment period, safety follow-up, and optional continuation
Double-blind randomized treatment withdrawal substudy
Timeline relative to the Launch-HTN double-blind period
Eligibility criteria
Inclusion criteria in the ClinicalTrials.gov record
Exclusion criteria in the ClinicalTrials.gov record
Additional criteria for the randomized treatment withdrawal substudy
Launch-HTN criteria that defined the presented cohort
Treatment
Registered arms and interventions
Open-label starting dose and background antihypertensive drugs
Study outcomes
Rationale for using change in automated office systolic blood pressure as the primary endpoint
Registered primary outcome measures
Efficacy endpoints in the AHA Scientific Sessions 2026 presentation
Prespecified endpoint: proportion achieving office systolic blood pressure below 130 mmHg
Safety endpoints and assessment periods
Placebo-controlled duration in the parent trial and the purpose of the extension
“First, the efficacy and safety of lorundrostat compared with placebo was evaluated for only 12 weeks. This is consistent with US Food and Drug Administration guidance limiting placebo-controlled studies of antihypertensive medications for this duration. However, eligible participants had the option to continue in an open-label extension trial (NCT05968430), which intends to provide safety and efficacy information relevant to longer-term use of lorundrostat.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Long-term exposure expected for drugs for chronic non-life-threatening conditions
Randomized withdrawal as a test of maintained effect in approved add-on products
Blood pressure reduction as the basis of cardiovascular benefit
Unattended automated office measurement in the parent trial
“After an initial 5-minute rest phase, 5 unattended seated measurements were performed with a 1-minute break between each reading; the last 4 measurements were used to calculate the mean and reduce within-participant variance in measuring BP.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Second, although ambulatory BP measurement is the gold standard for assessment of BP, unattended office BP was used as the primary outcome measure to reflect usual clinical practice.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Statistical analysis description
Number of participants (Planned and analyzed)
Enrollment across all parent studies
Launch-HTN cohort enrolled and analyzed
Planned sample size
No evidence found.
Number randomized in the randomized treatment withdrawal substudy
No evidence found.
Description of analysis sets
Population for the registered primary outcome
Estimand and handling of missing data
Population for the duration of treatment and the eGFR equation
Results
Participant disposition
Enrollment, completion, and duration of treatment in the Launch-HTN cohort
Participants enrolled from Advance-HTN and Explore-CKD
No evidence found.
Baseline characteristics
Baseline characteristics of the Launch-HTN cohort (safety population)
| Characteristic | Lorundrostat (N=632) |
|---|---|
| Age, mean ±SD, years | “61.2 ± 10.5” |
| Female, n (%) | “292 (46.2)” |
| Black or African American, n (%) | “155 (24.5)” |
| Hispanic or Latino, n (%) | “248 (39.2)” |
| BMI ≥30 kg/m2, n (%) | “395 (62.5)” |
| eGFR, mean ±SD, mL/min/1.73 m2 | “92.7 ± 17.4” |
| Office SBP, mean ±SD, mmHg | “148.5 ± 11.9” |
| 2 antihypertensive drugs, n (%) | “262 (41.5)” |
| 3 or more antihypertensive drugs, n (%) | “370 (58.5)” |
| Thiazide or thiazide-like diuretic, n (%) | “601 (95.1)” |
| ACE inhibitor or ARB, n (%) | “546 (86.4)” |
| Calcium channel blocker, n (%) | “295 (46.7)” |
| Beta blockers, n (%) | “209 (33.1)” |
Baseline office systolic blood pressure of the efficacy population
Efficacy results
Primary endpoint: change in office systolic blood pressure from Launch-HTN baseline to week 48
Proportion with office systolic blood pressure below 130 mmHg at week 48
Randomized treatment withdrawal substudy: status
Randomized treatment withdrawal substudy: change in automated office systolic blood pressure from week 12 to week 16
No evidence found.
Efficacy in participants enrolled from Advance-HTN and Explore-CKD
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Adverse events during the 36-week open-label period
| Participants, n (%) | Lorundrostat (N=632) |
|---|---|
| Any treatment-emergent adverse event | “413 (65.3)” |
| Moderate intensity | “141 (22.3)” |
| Severe intensity | “20 (3.2)” |
| Treatment-emergent adverse event leading to study drug withdrawal | “37 (5.9)” |
| Hyperkalemia leading to study drug withdrawal | “10 (1.6)” |
| Any serious adverse event | “27 (4.3)” |
| Death | “0” |
| Treatment-related serious treatment-emergent adverse event (investigator determined) | “2 (0.3)” |
| Hyperkalemia requiring trial drug modification (adverse event of special interest) | “32 (5.1)” |
| Hyponatremia requiring trial drug modification (adverse event of special interest) | “28 (4.4)” |
| Hypotension with symptoms (adverse event of special interest) | “13 (2.1)” |
| Serum potassium >6.0 mmol/L, confirmed per protocol repeat testing | “16 (2.5)” |
Definition of adverse events of special interest requiring drug modification
Serious adverse events, discontinuations, and hyperkalemia stated by the sponsor
Kidney function and serum potassium over time
Overall tolerability conclusion of the presenters
Study limitations
Summary
Transform-HTN is a phase 3, single-group, open-label extension registered with 1,076 participants from three parent studies (Launch-HTN, Advance-HTN, and Explore-CKD). The only results available as of November 2026 are for the Launch-HTN cohort, presented as congress slides and a company press release on November 8, 2026; no peer-reviewed publication and no posted registry results were located, and the record lists a certification or extension request for results submission first submitted on July 15, 2026. Of 808 participants who received lorundrostat in Launch-HTN, 632 (78%) enrolled, so the cohort is limited to participants who completed the parent trial and chose to continue, which may favor participants who tolerated and responded to treatment. The primary endpoint is a within-group change from the Launch-HTN baseline, which includes the 12-week double-blind period; after the 12-week double-blind period there was no concurrent control group except during the 4-week withdrawal substudy, and in Launch-HTN the placebo group's automated office systolic blood pressure fell by 7.9 mm Hg at week 6, so the 17.8 mmHg change at week 48 cannot be attributed entirely to lorundrostat. The efficacy analysis (504 participants) excluded participants randomized to placebo in the withdrawal substudy, whereas the safety analysis included all 632; missing week 48 values were imputed with a shift factor based on the parent trial's placebo group. The randomized treatment withdrawal substudy, the only randomized comparison in the trial, is a registered primary outcome (change in automated office systolic blood pressure from extension week 12 to week 16) and is listed as completed, but neither its sample size nor its results were located in any public document. Only the office systolic blood pressure change and the proportion below 130 mmHg were prespecified; the biomarker results were not. Serum creatinine was measured by an enzymatic assay in Launch-HTN and a Jaffe assay in the extension, which limits comparison of eGFR across the two periods. No quality-of-life or patient-reported outcome was reported, and no results were located for participants who entered from Advance-HTN or Explore-CKD.